Genedata Expressionist Enhances Automated Characterization of Biopharmaceuticals by Mass Spectrometry
Genedata reinforces support for Multi-Attribute Methods for developing and manufacturing biotherapeutics, and welcomes SCIEX as newest Ready-to-Run partner
January 28, 2020
Washington, DC, USA
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 13.5 at the 2020 WCBP Symposium. This release reinforces Genedata’s focus on supporting the implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their development and manufacturing. By further enhancing its best-in-class characterization capabilities and expanding its comprehensive overview of analytical results with novel, advanced visualizations, Genedata Expressionist 13.5 facilitates the automatic identification and definition of critical quality attributes (CQAs) and enables MAM implementations driven by the principle of quality by design.
Developed in close collaboration with partners across the biopharmaceutical industry, Genedata Expressionist provides unique workflow solutions for specific customer requirements. Out-of-the box data processing and analysis activities are configured to fully automate complex mass spectrometry-based workflows enabling users to effortlessly scale up their experimental throughput while improving the quality and consistency of results.
The new release includes the following highlights:
- New peptide mapping functionalities that enable searches for unexpected “wildcard” modifications and facilitate thorough review of results, accelerating analyses and providing best-in-class molecular characterization—important for next-generation MAM implementations.
- Novel intact mass analysis providing automated deconvolution over broad mass ranges up to 1 MDa with artefact suppression and a selection of full-range or zoomed views—improving the resolution and relative quantitation of coeluting species in analysis of intact proteins or subunits.
This release also sees Genedata welcoming SCIEX as its latest Ready-to-Run™ partner, enabling seamless integration with the newest SCIEX mass spectrometers and data formats—such as wiff and wiff2—and providing fast, high-performance processing of large volumes of raw data. The program provides innovative technology leaders like Genedata and SCIEX with a simple way to help joint customers automate complex data workflows, and eliminates the time and costs associated with integration services and projects, ultimately reducing customers’ total cost of ownership.
"The latest release of Genedata Expressionist—an important component of our Genedata Biopharma Platform—reinforces our continued commitment to support rapidly evolving needs of the biopharmaceutical industry, such as support of MAM. Genedata Expressionist enables our customers to efficiently scale up their internal data processing workflows, while at the same time improving result quality," commented Othmar Pfannes, Ph.D., CEO of Genedata. "Furthermore, we remain committed to partnering with leading technology providers such as SCIEX to offer our joint customers new solutions not only to accelerate discovery, development, and commercialization of novel biopharmaceuticals, but also to reduce costs by streamlining and automating complex analytical processes."
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.